Inspection Delay Puts Back Hanmi/Spectrum’s Rolontis
US Action Date Now Set For Feb '21
Executive Summary
US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued.
You may also be interested in...
Rising COVID-19 Disruption Of Korea's Global R&D
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Need a specific report? 1000+ reports available
Buy Reports